Nutrition Aspect of CancerImmunonutritioNCT07860372
Immunonutrition vs EPA-DHA Enriched Nutritional Support in Patients With Cancer Undergoing Surgery
An observational study of Nutrition Aspect of Cancer, run by Maimónides Biomedical Research Institute of Córdoba at 1 site in Spain.
Trial summary
To compare clinical and molecular effects of nutritional support (immunonutrition or EPA-DHA enriched oral nutritional supplements) in patients with cancer undergoing surgery. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Nutrition Aspect of Cancer
- What is being tested?
- Immunonutrition and EPA-DHA
- Type of treatment
- Pill or oral medicine
- How many people
- 80 participants
- Where
- 1 siteSpain
- Study dates
- 2 Nov 2026to 2 Nov 2028
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis
Who may be able to join
- Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis)
Who cannot join
- End-stage liver disease
- End-stage kidney disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
IMIBIC
Córdoba, Córdoba, 14004
Aura Herrera, aurita.dhm@gmail.com
About this study
Official title: IMMUNONUTRITION VS EPA-DHA ENRICHED NUTRITIONAL SUPPORT IN PATIENTS WITH CANCER UNDERGOING SURGERY
To compare clinical and molecular effects of nutritional support (immunonutrition or EPA-DHA enriched oral nutritional supplements) in patients with cancer undergoing surgery.
- Conditions
- Nutrition Aspect of Cancer
- Being tested
- Immunonutrition, EPA-DHA
- Keywords
- cancer, surgery, nutritional support, immunonutrition, EPA-DHA
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ImmunonutritionDietary supplement
Patients will receive nutritional advice and 2 oral nutritional supplements with arginine, fatty acids and nucleotides
EPA-DHADietary supplement
Patients will receive nutritional advice and 2 oral nutritional supplements enriched with EPA and DHA
| Study group | Role | What they receive |
|---|---|---|
| Patients with cancer undergoing surgery (primary tumor location: gastrointestinal tract, ovary) | Patients undergo nutritional prehabilitation before surgery Receives: Dietary Supplement: Immunonutrition; Dietary Supplement: EPA-DHA |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body composition changes
changes in fat mass, fat-free mass, lean mass and phase angle
Measured: 1-3 months
Secondary outcomes (2)
Cytokines changes
Changes in circulating cytokines (IL6, IL8, MIP10)
Measured: 1-3 months
Metabolites changes
Changes in circulating metabolites including lipids and muscle-related metabolites
Measured: 1-3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2026
- Study start2 Nov 2026 (estimated)
- Primary completion2 Nov 2027 (estimated)
- Study completion2 Nov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nutrition Aspect of CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Maimónides Biomedical Research Institute of Córdoba
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07860372
- Sponsor's protocol ID
- Immunonutrition vs EPA-DHA
- Acronym
- Immunonutritio
- Status last verified
- Sep 2026
- First submitted
- 30 Sep 2026
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- IMMUNONUTRITION VS EPA-DHA ENRICHED NUTRITIONAL SUPPORT IN PATIENTS WITH CANCER UNDERGOING SURGERY
- ClinicalTrials.gov ID
- NCT07860372
- Acronym / sponsor ID
- Immunonutritio / Immunonutrition vs EPA-DHA
- Conditions
- Nutrition Aspect of Cancer
- Keywords
- cancer, surgery, nutritional support, immunonutrition, EPA-DHA
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Maimónides Biomedical Research Institute of CórdobaUniversity, hospital or other
- Study start
- 2 Nov 2026 (estimated)
- Primary completion
- 2 Nov 2027 (estimated)
- Study completion
- 2 Nov 2028 (estimated)
- First posted
- 6 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare clinical and molecular effects of nutritional support (immunonutrition or EPA-DHA enriched oral nutritional supplements) in patients with cancer undergoing surgery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with cancer undergoing surgery (primary tumor location: gastrointestinal tract, ovary) | – | Dietary Supplement: Immunonutrition, Dietary Supplement: EPA-DHAPatients undergo nutritional prehabilitation before surgery |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis
Key inclusion criteria (1 listed)
- Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis)
Key exclusion criteria (2 listed)
- End-stage liver disease
- End-stage kidney disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ImmunonutritionPatients will receive nutritional advice and 2 oral nutritional supplements with arginine, fatty acids and nucleotides | Dietary supplement | Patients with cancer undergoing surgery (primary tumor location: gastrointestinal tract, ovary) |
| EPA-DHAPatients will receive nutritional advice and 2 oral nutritional supplements enriched with EPA and DHA | Dietary supplement | Patients with cancer undergoing surgery (primary tumor location: gastrointestinal tract, ovary) |
Primary outcome
Body composition changes
Time frame: 1-3 months
changes in fat mass, fat-free mass, lean mass and phase angle
2 secondary outcomes
Cytokines changes
Time frame: 1-3 months
Metabolites changes
Time frame: 1-3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Nutrition Aspect of Cancer
Not yet recruiting
Enhancing Cancer Care: RestoreMe App for Personalized Nutrition and Activity in Cancer Patients
Nutrition Aspect of Cancer, Cancer
Active, not recruitingObservational study
Malnutrition and Sarcopenia Screening in Chemotherapy Patients
Nutrition Aspect of Cancer, Sarcopenia
RecruitingObservational study
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Acute Lymphoblastic Leukemia, Nutrition Aspect of Cancer
Active, not recruitingObservational study
Mesenteric Lymph Node Metastasis and Nutritional Status After Bowel Resection for Ovarian Cancer
Progression-Free Survival, Overall Survival
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Nutrition Aspect of Cancer, run by Maimónides Biomedical Research Institute of Córdoba at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jose Carlos Garrido, PhD (957 736 571, josecarlos.garrido@imibic.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body composition changes (time frame: 1-3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026; AzTrials last refreshed its copy on 2 Nov 2026.